Connection
Vyga Kaufmann to Genetic Variation
This is a "connection" page, showing publications Vyga Kaufmann has written about Genetic Variation.
|
|
| |
Connection Strength |
|
 |
|
 |
| |
0.051 |
|
|
|
-
Lerman C, Wileyto EP, Patterson F, Rukstalis M, Audrain-McGovern J, Restine S, Shields PG, Kaufmann V, Redden D, Benowitz N, Berrettini WH. The functional mu opioid receptor (OPRM1) Asn40Asp variant predicts short-term response to nicotine replacement therapy in a clinical trial. Pharmacogenomics J. 2004; 4(3):184-92.
Score: 0.039
-
Lerman C, Jepson C, Wileyto EP, Epstein LH, Rukstalis M, Patterson F, Kaufmann V, Restine S, Hawk L, Niaura R, Berrettini W. Role of functional genetic variation in the dopamine D2 receptor (DRD2) in response to bupropion and nicotine replacement therapy for tobacco dependence: results of two randomized clinical trials. Neuropsychopharmacology. 2006 Jan; 31(1):231-42.
Score: 0.011